In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Pharmaceutica NV

Division of Johnson & Johnson
www.janssenpharmaceutica.be

Latest From Janssen Pharmaceutica NV

Piramal Critical Care Docks For China Push

Peter DeYoung, CEO of Piramal Critical Care, tells Scrip about his plans to take the group’s inhalation anesthesia portfolio to China and talks of the greater “competitive intensity” in the US amid quicker ANDA approvals by the FDA. Timelines around the potential US launch of the inhaled anesthetic agent, desflurane, however, appear hazy.
Commercial Strategy

Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3

A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.

StartUps and SMEs Financing

Deals Shaping The Medical Industry, October 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.

Deals BioPharmaceutical

Janssen's Darunavir-Based Single-Tablet Effective In Late-Stage Switching Study

Switching to a once-daily single tablet containing four constituents that is centered on Janssen's protease inhibitor darunavir was non-inferior to other combination therapies after 48 weeks of therapy, say researchers running the Phase III EMERALD study.

Clinical Trials Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register